|
|
|
|
| LEADER |
00000cam a2200000 a 4500 |
| 001 |
SCIDIR_on1136965053 |
| 003 |
OCoLC |
| 005 |
20231120010433.0 |
| 006 |
m o d |
| 007 |
cr un|---aucuu |
| 008 |
200118s2020 ne o 001 0 eng d |
| 040 |
|
|
|a EBLCP
|b eng
|e pn
|c EBLCP
|d OPELS
|d OCLCF
|d UKAHL
|d OCLCQ
|d N$T
|d YDX
|d OCLCQ
|d OCLCO
|d K6U
|d OCLCQ
|d OCLCO
|
| 019 |
|
|
|a 1136523848
|
| 020 |
|
|
|a 9780128177792
|q (electronic bk.)
|
| 020 |
|
|
|a 0128177799
|q (electronic bk.)
|
| 020 |
|
|
|z 9780128177785
|q (print)
|
| 020 |
|
|
|z 0128177780
|
| 035 |
|
|
|a (OCoLC)1136965053
|z (OCoLC)1136523848
|
| 050 |
|
4 |
|a RS199.5
|
| 082 |
0 |
4 |
|a 615/.6
|2 23
|
| 245 |
0 |
0 |
|a Nanopharmaceuticals :
|b expectations and realities of multifunctional drug delivery systems.
|n Volume 1 /
|c edited by Ranjita Shegokar.
|
| 260 |
|
|
|a Amsterdam :
|b Elsevier,
|c 2020.
|
| 300 |
|
|
|a 1 online resource (246 pages)
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 588 |
0 |
|
|a Print version record.
|
| 505 |
0 |
|
|a Front Cover -- NANOPHARMACEUTICALS -- NANOPHARMACEUTICALS -- Copyright -- Contents -- Contributors -- Preface -- 1 -- Solid lipid nanoparticles (SLN): prediction of toxicity, metabolism, fate and physicochemical properties -- 1. Introduction -- 2. Toxicity profiling -- 3. Physicochemical properties -- 3.1 Encapsulation parameters -- 3.2 Particle size -- 3.3 Zeta potential -- 3.4 Particle morphology -- 3.5 Differential scanning calorimetry -- 3.6 Stability of formulations and release profile -- 4. Administration routes and drug bioavailability -- 4.1 Topical and dermal routes
|
| 505 |
8 |
|
|a 4.2 Ocular delivery -- 4.3 Oral administration -- 4.4 Parenteral administration -- 4.5 Nasal and pulmonary delivery -- 5. Conclusions -- Abbreviations -- Acknowledgments -- References -- 2 -- Role of nanocarriers and their surface modification in targeting delivery of bioactive compounds -- 1. Bioactive compounds as promising therapeutic agents -- 1.1 Curcuma sp -- 1.2 Zingiber officinale -- 1.3 Silybum marianum L -- 1.4 Gnetum gnemon -- 1.5 Physalis angulata -- 2. Complexity of bioactive compounds -- 3. Biological barriers -- 3.1 Physical barriers -- 3.2 Biochemical barriers
|
| 505 |
8 |
|
|a 4. Nanocarrier: a strategy to overcome biological barriers -- 4.1 Lipid-based nanocarrier systems -- 4.1.1 Liposomes -- 4.1.2 Nanoemulsions -- 4.1.3 Solid lipid nanoparticles -- 5. Safe-by-design bioactive-loaded nanocarrier system development -- 6. Cellular uptake capability of bioactive-loaded nanocarrier system -- 7. Surface modification of nanocarriers -- 8. Biokinetic profile of bioactive-loaded nanocarriers -- 9. Challenges of bioactive-loaded nanocarrier to clinical translation -- 9.1 Patents on herbal nanoparticles for breast cancer -- 10. Conclusion -- References
|
| 505 |
8 |
|
|a 3 -- Polymeric nanomicelles as versatile tool for multidrug delivery in chemotherapy -- 1. Introduction -- 2. Micelles, principles and characterization -- 2.1 Preparation methods -- 2.2 Characterization techniques -- 2.3 Drug-loading methods -- 3. Polymeric micelles for codelivery of chemotherapeutics -- 3.1 Codelivery of chemotherapeutics to overcome multidrug resistance -- 3.1.1 Codelivery of chemotherapeutics and chemosensitizers -- 3.1.2 Codelivery of chemotherapeutics and downregulating gene agents
|
| 505 |
8 |
|
|a 3.2 Codelivery of chemotherapeutics to achieve synergistic effects by methods other than effects on MDR -- 3.3 Codelivery of chemotherapeutics to mitigate side effects -- 4. Stimuli-responsive codelivery of polymeric micelles -- 4.1 pH-sensitive codelivery systems -- 4.2 Redox-sensitive codelivery systems -- 5. Targeted codelivery of polymeric micelles -- 6. Application of polymeric micelles in codelivery for multiple therapies -- 6.1 Chemo-immunotherapy -- 6.2 Chemo-angiogenic therapy -- 6.3 Chemo-photothermal therapy -- 6.4 Chemo-radiotherapy -- 6.5 Chemo-enzyme prodrug therapy
|
| 500 |
|
|
|a 7. Conclusions
|
| 500 |
|
|
|a Includes index.
|
| 650 |
|
0 |
|a Drug delivery systems.
|
| 650 |
|
0 |
|a Nanoparticles.
|
| 650 |
|
2 |
|a Drug Delivery Systems
|0 (DNLM)D016503
|
| 650 |
|
2 |
|a Nanoparticles
|0 (DNLM)D053758
|
| 650 |
|
6 |
|a Syst�emes d'administration de m�edicaments.
|0 (CaQQLa)000260397
|
| 650 |
|
6 |
|a Nanoparticules.
|0 (CaQQLa)201-0262530
|
| 650 |
|
7 |
|a Drug delivery systems
|2 fast
|0 (OCoLC)fst00898667
|
| 650 |
|
7 |
|a Nanoparticles
|2 fast
|0 (OCoLC)fst01032624
|
| 700 |
1 |
|
|a Shegokar, Ranjita.
|
| 776 |
0 |
8 |
|i Print version:
|a Shegokar, Ranjita.
|t Nanopharmaceuticals : Expectations and Realities of Multifunctional Drug Delivery Systems, Volume 1.
|d San Diego : Elsevier, �2020
|z 9780128177785
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780128177785
|z Texto completo
|
